Open AccessP1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE PHASE 3 ECHELON‐3 STUDY
Author(s) -
Bartlett N. L.,
Yasenchak C. A.,
Ashraf K. K.,
Harwin W. N.,
Orcutt J.,
Kuriakose P.,
Zinzani P. L.,
Mamidipalli A.,
Fenton K.,
Glenn C.,
Nowakowski G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847576.88118.d6
Subject(s) - medicine , lenalidomide , brentuximab vedotin , rituximab , oncology , phases of clinical research , clinical trial , lymphoma , surgery , cd30 , multiple myeloma